Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Tarlatamab by Amgen for Neuroendocrine Cancer: Likelihood of Approval
Tarlatamab is under clinical development by Amgen and currently in Phase I for Neuroendocrine Cancer. According to GlobalData, Phase I...
Tarlatamab by Amgen for Prostate Cancer: Likelihood of Approval
Tarlatamab is under clinical development by Amgen and currently in Phase I for Prostate Cancer. According to GlobalData, Phase I...
Tarlatamab by Amgen for Small-Cell Lung Cancer: Likelihood of Approval
Tarlatamab is under clinical development by Amgen and currently in Phase III for Small-Cell Lung Cancer. According to GlobalData, Phase...